This WCLC 2026 interview with Prof. Jonathan W. Goldman examines the rationale, patient selection, and clinical implications of extended-interval tarlatamab dosing in small-cell lung cancer.
Organized by the International Association for the Study of Lung Cancer (IASLC), the World Conference on Lung Cancer (WCLC) brings together clinicians, researchers, nurses, and other thoracic oncology professionals to share major advances in lung cancer research and clinical care. WCLC 2026 took place in Seoul, Republic of Korea, from September 12 to 15.
Prof. Jonathan W. Goldman is Professor of Medicine at the David Geffen School of Medicine at UCLA and Director of Clinical Trials in Thoracic Oncology at UCLA Jonsson Comprehensive Cancer Center. Prof. Goldman’s research focuses on targeted therapy, immunotherapy, and early drug development in lung cancer.
Key highlights from this clip:
● The rationale for evaluating tarlatamab every three or four weeks
● Treatment convenience and pharmacokinetic and pharmacodynamic considerations
● Patient selection for extended-interval dosing
● Integration with immune checkpoint inhibitors, chemotherapy, and maintenance treatment
● Balancing efficacy, overlapping toxicities, and treatment adherence
● Confirmatory trial design, endpoint selection, and lessons for BiTE development
This video is intended for medical education and professional discussion.